Boye N P, Vale J R
Eur J Clin Pharmacol. 1977;11(1):11-4. doi: 10.1007/BF00561781.
The bronchial effect of intravenous atenolol (ICI 66.082) has been studied in a double-blind cross over trial in 10 patients with pronounced, labile bronchial asthama. A single i.v. dose of atenolol 3 mg. sufficient to cause a fall in heart rate and systolic blood pressure at rest, induced only a slight and clincially almost negligible impairment of ventilatory function. An ordinary therapeutic dose of salbutamol by inhalation far outweighed the bronchial effect of atenolol. The drug appears promising with regard to its cardio-selective properties.
在一项双盲交叉试验中，对10名患有严重、易变支气管哮喘的患者研究了静脉注射阿替洛尔（ICI 66.082）的支气管效应。静脉注射3毫克阿替洛尔的单次剂量足以使静息心率和收缩压下降，仅引起通气功能轻微且临床上几乎可忽略不计的损害。吸入普通治疗剂量的沙丁胺醇对支气管的作用远远超过阿替洛尔。就其心脏选择性特性而言，该药物似乎很有前景。
